NSPR

SEC source: 0001493152-23-018327 · ownership.xml · derivative · entry 2

Slosman Marvin · CIK 0001796908 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,406

Underlying: Common Stock · 348,380 shares

Expires 2033-05-17

F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018327 · ownership.xml · nonDerivative · entry 1

Slosman Marvin · CIK 0001796908 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,288,620

F1 · shares: These restricted stock units vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018325 · ownership.xml · derivative · entry 2

Shore Craig · CIK 0001517387 · CFO and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,270

Underlying: Common Stock · 174,190 shares

Expires 2033-05-17

F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018325 · ownership.xml · nonDerivative · entry 1

Shore Craig · CIK 0001517387 · CFO and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 641,219

F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018326 · ownership.xml · derivative · entry 3

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,228

Underlying: Common Stock · 75,220 shares

Expires 2033-05-17

F3 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018326 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 268,000

F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018337 · ownership.xml · derivative · entry 2

Gleason Shane Thomas · CIK 0001966214 · VP Global Marketing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,480

Underlying: Common Stock · 85,480 shares

Expires 2033-05-17

F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018337 · ownership.xml · nonDerivative · entry 1

Gleason Shane Thomas · CIK 0001966214 · VP Global Marketing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,450

F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018336 · ownership.xml · derivative · entry 3

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,016

Underlying: Common Stock · 49,750 shares

Expires 2033-05-17

F3 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018336 · ownership.xml · nonDerivative · entry 1

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 192,087

F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018335 · ownership.xml · derivative · entry 2

Tommasoli Andrea · CIK 0001969462 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,481

Underlying: Common Stock · 59,690 shares

Expires 2033-05-17

F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018335 · ownership.xml · nonDerivative · entry 1

Tommasoli Andrea · CIK 0001969462 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,453

F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018334 · ownership.xml · derivative · entry 2

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,013

Underlying: Common Stock · 49,750 shares

Expires 2033-05-17

F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-018334 · ownership.xml · nonDerivative · entry 1

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,850

F1 · shares: These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of May 17, 2024, May 17, 2025 and May 17, 2026, subject to the Reporting Person's continued service.

SEC source: 0001493152-23-017787 · ownership.xml · derivative · entry 5

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,624

Underlying: Common Stock · 30,624 shares

Expires not disclosed

F9 · shares: The aggregate number of warrants reported in this row consists of 30,624 Series K Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F10 · derivative.expiration_date: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.

SEC source: 0001493152-23-017787 · ownership.xml · derivative · entry 4

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,625

Underlying: Common Stock · 30,625 shares

Expires not disclosed

F7 · shares: The aggregate number of warrants reported in this row consists of 30,625 Series J Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F8 · derivative.expiration_date: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.

SEC source: 0001493152-23-017787 · ownership.xml · derivative · entry 3

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,624

Underlying: Common Stock · 30,624 shares

Expires not disclosed

F5 · shares: The aggregate number of warrants reported in this row consists of 30,624 Series I Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F6 · derivative.expiration_date: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).

SEC source: 0001493152-23-017787 · ownership.xml · derivative · entry 2

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,625

Underlying: Common Stock · 30,625 shares

Expires not disclosed

F3 · shares: The aggregate number of warrants reported in this row consists of 30,625 Series H Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F4 · derivative.expiration_date: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.

SEC source: 0001493152-23-017787 · ownership.xml · nonDerivative · entry 1

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 233,545

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

SEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 6

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires not disclosed

F10 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series K Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F11 · derivative.expiration_date: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.

F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 5

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires not disclosed

F8 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series J Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F9 · derivative.expiration_date: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.

F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 4

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires not disclosed

F6 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series I Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F7 · derivative.expiration_date: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).

F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-23-017792 · ownership.xml · derivative · entry 3

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires not disclosed

F4 · shares: The aggregate number of warrants reported in this row consists of 87,500 Series H Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F5 · derivative.expiration_date: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.

F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-23-017792 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 248,534

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F3 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-23-017791 · ownership.xml · derivative · entry 5

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,624

Underlying: Common Stock · 30,624 shares

Expires not disclosed

F9 · shares: The aggregate number of warrants reported in this row consists of 30,624 Series K Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F10 · derivative.expiration_date: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.

SEC source: 0001493152-23-017791 · ownership.xml · derivative · entry 4

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,625

Underlying: Common Stock · 30,625 shares

Expires not disclosed

F7 · shares: The aggregate number of warrants reported in this row consists of 30,625 Series J Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F8 · derivative.expiration_date: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.

SEC source: 0001493152-23-017791 · ownership.xml · derivative · entry 3

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,624

Underlying: Common Stock · 30,624 shares

Expires not disclosed

F5 · shares: The aggregate number of warrants reported in this row consists of 30,624 Series I Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F6 · derivative.expiration_date: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).

SEC source: 0001493152-23-017791 · ownership.xml · derivative · entry 2

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,625

Underlying: Common Stock · 30,625 shares

Expires not disclosed

F3 · shares: The aggregate number of warrants reported in this row consists of 30,625 Series H Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F4 · derivative.expiration_date: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.

SEC source: 0001493152-23-017791 · ownership.xml · nonDerivative · entry 1

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,590

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

SEC source: 0001493152-23-017789 · ownership.xml · derivative · entry 6

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 61,248

Underlying: Common Stock · 61,248 shares

Expires not disclosed

F10 · shares: The aggregate number of warrants reported in this row consists of 61,249 Series K Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F11 · derivative.expiration_date: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.

F3 · ownership.nature: These securities are held by the Michael Berman Revocable Trust.

SEC source: 0001493152-23-017789 · ownership.xml · derivative · entry 5

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 61,249

Underlying: Common Stock · 61,249 shares

Expires not disclosed

F8 · shares: The aggregate number of warrants reported in this row consists of 61,249 Series J Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F9 · derivative.expiration_date: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.

F3 · ownership.nature: These securities are held by the Michael Berman Revocable Trust.

SEC source: 0001493152-23-017789 · ownership.xml · derivative · entry 4

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 61,248

Underlying: Common Stock · 61,248 shares

Expires not disclosed

F6 · shares: The aggregate number of warrants reported in this row consists of 61,248 Series I Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F7 · derivative.expiration_date: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).

F3 · ownership.nature: These securities are held by the Michael Berman Revocable Trust.

SEC source: 0001493152-23-017789 · ownership.xml · derivative · entry 3

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 61,249

Underlying: Common Stock · 61,249 shares

Expires not disclosed

F4 · shares: The aggregate number of warrants reported in this row consists of 61,249 Series H Warrants that were acquired in the Private Placement.

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F5 · derivative.expiration_date: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.

F3 · ownership.nature: These securities are held by the Michael Berman Revocable Trust.

SEC source: 0001493152-23-017789 · ownership.xml · nonDerivative · entry 1

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 122,497

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

F2 · price: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F3 · ownership.nature: These securities are held by the Michael Berman Revocable Trust.

SEC source: 0001493152-23-010853 · ownership.xml · nonDerivative · entry 1

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,296

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that are earned and vested upon grant and are issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2023.

SEC source: 0001493152-23-010850 · ownership.xml · nonDerivative · entry 1

Arnold Kathryn · CIK 0001861350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,951

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that are earned and vested upon grant and are issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2023.

SEC source: 0001493152-23-010852 · ownership.xml · nonDerivative · entry 1

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,827

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that are earned and vested upon grant and are issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2023.

SEC source: 0001493152-23-010854 · ownership.xml · nonDerivative · entry 1

Kester Thomas J · CIK 0001299870 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,341

F1 · shares: The shares of common stock reported in this row represent shares of restricted stock that are earned and vested upon grant and are issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2023.

SEC source: 0001493152-22-023735 · ownership.xml · nonDerivative · entry 1

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,194

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $1.72, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

SEC source: 0001493152-21-032757 · ownership.xml · nonDerivative · entry 1

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,694

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.09 to $3.05, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

SEC source: 0001493152-21-030337 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 73,534

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.49 to $3.52, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-030119 · ownership.xml · nonDerivative · entry 2

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 61,497

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.55, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-030119 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 43,125

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-030004 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 39,948

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-029925 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 38,748

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-029722 · ownership.xml · nonDerivative · entry 2

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 20,420

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-029722 · ownership.xml · nonDerivative · entry 1

Stuka Paul · CIK 0001528577 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 19,216

F1 · ownership.nature: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

SEC source: 0001493152-21-029222 · ownership.xml · nonDerivative · entry 2

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,301

SEC source: 0001493152-21-029222 · ownership.xml · nonDerivative · entry 1

ROUBIN GARY S · CIK 0001162533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,011

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $3.77, inclusive. The Reporting Person undertakes to provide to InspireMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).

SEC source: 0001493152-21-028170 · ownership.xml · derivative · entry 2

BERMAN MICHAEL · CIK 0001186801 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,749

Underlying: Common Stock · 5,749 shares

Expires 2031-11-10

F2 · derivative.exercise_date: The options vest and become exercisable in three equal installments, with 1/3 vesting on each of November 10, 2022, November 10, 2023 and November 10, 2024, subject to the Reporting Person's continued service.